Tiespectus
Phase 3Small molecule
Tiespectus is one of 16 small molecule programs targeting Macular Degeneration. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Macular Degeneration
#DrugCompanyPhaseTrials
1Vabysmo
RocheApproved
Copaxone
TevaApproved
Iheezo
BB. Braun Medical Inc.
Approved
Avastin
RochePhase 3
Kenalog
BBausch Health Americas, Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Visudyne
BBausch Health Americas, Inc.
Approved
OTX-TKI
OOcular Therapeutix, Inc.
Phase 3
Tiespectus
EEyeBiotech Ltd.
Phase 3
Faricimab Injection [vabysmo]
CCincinnati Eye Institute, Southwest Ohio
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Macular Degeneration2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tiespectus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEyeBiotech Ltd.